4.7 Article

The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors

Journal

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.ijrobp.2018.09.010

Keywords

-

Funding

  1. ARMO BioSciences
  2. AstraZeneca/MedImmune
  3. Bristol-Myers Squibb
  4. Celldex
  5. Merck
  6. Varian
  7. BMS

Ask authors/readers for more resources

Purpose: Therapeutic radiation has conflicting immune effects: radiation therapy (RT)-induced immunogenic cell death can contribute to immune response, but lymphocytes are also sensitive to RT. It is unknown whether palliative RT leads to lymphopenia in patients treated with immune checkpoint inhibitors (ICIs) and whether this affects outcomes. As such, we sought to assess the impact of palliative RT on circulating lymphocyte count and neutrophil-to-lymphocyte ratio in patients being treated with PD-1edirected ICI and associations with survival. Methods and Materials: We identified patients from 5 radiation oncology centers, treated with palliative RT and either pembrolizumab or nivolumab with non-small cell lung cancer, metastatic melanoma, and renal cell carcinoma. Patients who received intervening cytotoxic chemotherapy were excluded. We recorded absolute lymphocyte count (ALC) and neutrophil-to-lymphocyte ratio before and after palliative RT and at the start of ICI. Survival was analyzed using the Kaplan-Meier method and Cox proportional hazard models. Results: One hundred ten patients received 225 courses of palliative RT. Median change in ALC after RT was -161 cells/mL. Decreases in ALC were greater with RT to the spine, lung/mediastinum, and chest wall compared with the brain, extremity, or abdomen/pelvis (P = .002) and after courses >5 fractions (P = .003). Extracranial and >5-fraction RT was associated with increased odds of severe lymphopenia (ALC <500) at the end of RT (odds ratio [OR], 3.7; P = .001; and OR, 3.9; P = .001, respectively). Patients who developed RT-induced severe lymphopenia were more likely to have severe lymphopenia when ICI was initiated (OR, 6.4; P = .0001), particularly when RT was administered in the previous 3 months (OR, 189; P < .0001). Severe lymphopenia at onset of ICI therapy was associated with increased mortality on multivariable analysis (hazard ratio, 2.1; P = .03). Conclusions: Extracranial or prolonged courses of RT increase the risk of severe lymphopenia, which is associated with poorer survival in patients treated with ICI. (C) 2018 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer

Martin T. King, David D. Yang, Vinayak Muralidhar, Brandon Mahal, Santino Butler, Phillip M. Devlin, Larissa J. Lee, Kent W. Mouw, Neil M. Martin, Anthony V. D'Amico, Paul L. Nguyen, Peter F. Orio

BRACHYTHERAPY (2019)

Article Oncology

Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival?

Alexander P. Cole, Sean A. Fletcher, Sebastian Berg, Junaid Nabi, Brandon A. Mahal, Guru P. Sonpavde, Paul L. Nguyen, Stuart R. Lipsitz, Maxine Sun, Toni K. Choueiri, Mark A. Preston, Adam S. Kibel, Quoc-Dien Trinh

CANCER (2019)

Article Oncology

Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas

Shuang G. Zhao, William S. Chen, Rajdeep Das, S. Laura Chang, Scott A. Tomlins, Jonathan Chou, David A. Quigley, Ha X. Dang, Travis J. Barnard, Brandon A. Mahal, Ewan A. Gibb, Yang Liu, Elai Davicioni, Linda R. Duska, Edwin M. Posadas, Shruti Jolly, Daniel E. Spratt, Paul L. Nguyen, Christopher A. Maher, Eric J. Small, Felix Y. Feng

CLINICAL CANCER RESEARCH (2019)

Article Urology & Nephrology

Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer

David D. Yang, Brandon A. Mahal, Vinayak Muralidhar, Neil E. Martin, Peter F. Orio, Kent W. Mouw, Martin T. King, Toni K. Choueiri, Quoc-Dien Trinh, Karen E. Hoffman, Daniel E. Spratt, Felix Y. Feng, Paul L. Nguyen

EUROPEAN UROLOGY (2019)

Letter Urology & Nephrology

Prostate Cancer Genomic-risk Differences Between African-American and White Men Across Gleason Scores

Brandon A. Mahal, Mohammed Alshalalfa, Daniel E. Spratt, Elai Davicioni, Shuang G. Zhao, Felix Y. Feng, Timothy R. Rebbeck, Paul L. Nguyen, Franklin W. Huang

EUROPEAN UROLOGY (2019)

Letter Medicine, General & Internal

Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015

Brandon A. Mahal, Santino Butler, Idalid Franco, Daniel E. Spratt, Timothy R. Rebbeck, Anthony V. D'Amico, Paul L. Nguyen

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)

Letter Oncology

Trends in Smoking and e-Cigarette Use Among US Patients With Cancer, 2014-2017

Nina N. Sanford, David J. Sher, Xiaohan Xu, Ayal A. Aizer, Brandon A. Mahal

JAMA ONCOLOGY (2019)

Article Oncology

Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types

William S. Chen, Mohammed Alshalalfa, Shuang G. Zhao, Yang Liu, Brandon A. Mahal, David A. Quigley, Ting Wei, Elai Davicioni, Timothy R. Rebbeck, Philip W. Kantoff, Christopher A. Maher, Karen E. Knudsen, Eric J. Small, Paul L. Nguyen, Felix Y. Feng

CLINICAL CANCER RESEARCH (2019)

Review Oncology

Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies

William C. Jackson, Jessica Silva, Holly E. Hartman, Robert T. Dess, Amar U. Kishan, Whitney H. Beeler, Laila A. Gharzai, Elizabeth M. Jaworski, Rohit Mehra, Jason W. D. Hearn, Todd M. Morgan, Simpa S. Salami, Matthew R. Cooperberg, Brandon A. Mahal, Payal D. Soni, Samuel Kaffenberger, Paul L. Nguyen, Neil Desai, Felix Y. Feng, Zachary S. Zumsteg, Daniel E. Spratt

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)

Letter Medicine, General & Internal

Racial Disparities in Low-Risk Prostate Cancer Reply

Brandon A. Mahal, Franklin W. Huang

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)

Article Oncology

Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer

Santino S. Butler, Brandon A. Mahal, Nayan Lamba, Matthew Mossanen, Neil E. Martin, Kent W. Mouw, Paul L. Nguyen, Vinayak Muralidhar

CANCER (2019)

Article Oncology

Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database

Amandeep R. Mahal, Santino Butler, Idalid Franco, Vinayak Muralidhar, Dalia Larios, Luke R. G. Pike, Shuang G. Zhao, Nina N. Sanford, Robert T. Dess, Felix Y. Feng, Anthony V. D'Amico, Daniel E. Spratt, James B. Yu, Paul L. Nguyen, Timothy R. Rebbeck, Brandon A. Mahal

CANCER (2019)

Article Oncology

Racial disparities in brachytherapy administration and survival in women with locally advanced cervical cancer

Stephanie Alimena, David D. Yang, Alexander Melamed, Brandon A. Mahal, Michael J. Worley, Sarah Feldman, Kevin M. Elias, Peter F. Orio, Larissa J. Lee, Martin King

GYNECOLOGIC ONCOLOGY (2019)

Article Oncology

Genomic Validation of 3-Tiered Clinical Subclassification of High-Risk Prostate Cancer

Vinayak Muralidhar, Jingbin Zhang, Qiqi Wang, Brandon A. Mahal, Santino S. Butler, Daniel E. Spratt, Elai Davicioni, Oliver Sartor, Felix Y. Feng, Kent W. Mouw, Paul L. Nguyen

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)

Letter Oncology

The Use of e-Cigarettes in Patients With Cancer-A Double Shipwreck Reply

Nina N. Sanford, Brandon A. Mahal

JAMA ONCOLOGY (2019)

No Data Available